Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2014

01-05-2014 | Research Article

The effect of CYP1A1 and CYP1A2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis

Authors: Huiping Xue, Yan Lu, Zeyun Xue, Bing Lin, Jinxian Chen, Feng Tang, Gang Huang

Published in: Tumor Biology | Issue 5/2014

Login to get access

Abstract

Potential Cytochrome P450s (CYPs) 1A1 MspI, 1A1 Ile462Val, 1A2*1 F, and/or 1A2*1C polymorphisms have been implicated in gastric cancer risk among different ethnicities. We aimed to explore the effect of CYP 1A1 MspI, 1A1 Ile462Val, 1A2*1 F, and/or 1A2*1C polymorphisms on the susceptibility to gastric cancer among different ethnicities through a systematic review and meta-analysis. Each initially included article was scored for quality appraisal. Desirable data were extracted and registered into databases. A number of 11 studies were ultimately eligible for the meta-analysis of CYP1A1 MspI polymorphism, eight studies for the meta-analysis of 1A1 Ile462Val polymorphism, and two studies for the meta-analysis of 1A2*1 F polymorphism. None of genetic model was evidently suggested, and thus all the genetic models were presented. Potential sources of heterogeneity were sought out via subgroup and sensitivity analyses, and publication biases were estimated. In our meta-analysis, significant results could be found in mutational heterozygous CT genotype, compared with wild TT genotype, among large sample size subgroup for CYP1A1 MspI polymorphism. Regarding CYP1A1 Ile462Val polymorphism, no statistically significant results could be found. For CYP1A2*1 F polymorphism, mutational heterozygous AC genotype, compared with wild-type AA, has deleterious effects, whereas mutational homozygous CC genotype, compared with mutational heterozygous type AC, has protective effects but lacks statistically significant difference despite its a proximity to 0.05. Combined mutational homozygous CC genotype and wild-type homozygous AA, compared with mutational heterozygous AC genotype, has protective effects. Our meta-analysis suggests no associations between CYP1A1 Ile462Val polymorphism and gastric cancer, but possible associations between CYP1A1 MspI and CYP1A2*1 F polymorphisms and gastric cancer, which needs to be further reinforced or refuted among different ethnicities in well-designed large-scale high-quality studies.
Appendix
Available only for authorised users
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.CrossRefPubMed
2.
Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology. 2002;123:1793–803.CrossRefPubMed
3.
Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol. 2010;25(10):1604–17.CrossRefPubMed
4.
Xue H, Liu J, Lin B, Wang Z, Sun J, et al. A Meta-analysis of interleukin-8-251 promoter polymorphism associated with gastric cancer risk. PLoS One. 2012;7(1):e28083.CrossRefPubMedPubMedCentral
5.
Gonzalez FJ. The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility. Reprod Toxicol. 1997;11:397–412.CrossRefPubMed
6.
Constable A, Varga N, Josephy PD, Guy P, Turesky RJ. Evaluation of Escherichia coli DJ4309 expressing human P450 1A2 in mutagenicity testing of complex food mixtures. Mutat Res. 1999;442(2):79–87.CrossRefPubMed
7.
Al-Buheissi SZ, Cole KJ, Hewer A, Kumar V, Bryan RL, Hudson DL, et al. The expression of xenobiotic-metabolizing enzymes in human prostate and in prostate epithelial cells (PECs) derived from primary cultures. Prostate. 2006;66(8):876–85.CrossRefPubMed
8.
McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, Tukey RH. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res. 1990;50(11):3367–76.PubMed
9.
Pavanello S, Clonfero E. Biological indicators of genotoxic risk and metabolic polymorphisms. Mutat Res. 2000;463:285–308.CrossRefPubMed
10.
Wright CM, Larsen JE, Colosimo ML, Barr JJ, Chen L, McLachlan RE, et al. Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. Eur Respir J. 2010;35(1):152–9.CrossRefPubMed
11.
Sachse C, Bhambra U, Smith G, et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol. 2003;55:68–76.CrossRefPubMedPubMedCentral
12.
13.
Darazy M, Balbaa M, Mugharbil A, Saeed H, Sidani H, Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer among Lebanese. Genet Test Mol Biomarkers. 2011;15(6):423–9.CrossRefPubMed
14.
Luo YP, Chen HC, Khan MA, Chen FZ, Wan XX, Tan B, et al. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol. 2011;32(1):215–22.CrossRefPubMed
15.
Kobayashi M, Otani T, Iwasaki M, Natsukawa S, Shaura K, Koizumi Y, et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case–control study in Japan. Gastric Cancer. 2009;12(4):198–205.CrossRefPubMed
16.
Malik MA, Upadhyay R, Mittal RD, Zargar SA, Modi DR, Mittal B. Role of xenobiotic-metabolizing enzyme gene polymorphisms and interactions with environmental factors in susceptibility to gastric cancer in Kashmir Valley. J Gastrointest Cancer. 2009;40(1–2):26–32.CrossRefPubMed
17.
Boccia S, Sayed-Tabatabaei FA, Persiani R, Gianfagna F, Rausei S, Arzani D, et al. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case–control study in an Italian population. BMC Cancer. 2007;7:206.CrossRefPubMedPubMedCentral
18.
Wideroff L, Vaughan TL, Farin FM, Gammon MD, Risch H, Stanford JL, et al. GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev. 2007;31(3):233–6.CrossRefPubMedPubMedCentral
19.
González A, Ramírez V, Cuenca P, Sierra R. Polymorphisms in detoxification genes CYP1A1, CYP2E1, GSTT1 and GSTM1 in gastric cancer susceptibility. Rev Biol Trop. 2004;52(3):591–600. Spanish.PubMed
20.
Lee K, Cáceres D, Varela N, Csendes DA, Ríos RH, Quiñones SL. Allelic variants of cytochrome P4501A1 (CYP1A1), glutathione S transferase M1 (GSTM1) polymorphisms and their association with smoking and alcohol consumption as gastric cancer susceptibility biomarkers. Rev Med Chil. 2006;134(9):1107–15. Spanish.CrossRefPubMed
21.
Agudo A, Sala N, Pera G, Capellá G, Berenguer A, García N, et al. Polymorphisms in metabolic genes related to tobacco smoke and the risk of gastric cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2427–34.CrossRefPubMed
22.
Ma JX, Zhang KL, Liu X, Ma YL, Pei LN, Zhu YF, et al. Concurrent expression of aryl hydrocarbon receptor and CYP1A1 but not CYP1A1 MspI polymorphism is correlated with gastric cancers raised in Dalian. China Cancer Lett. 2006;240(2):253–60.CrossRefPubMed
23.
Shen J, Wang RT, Xu YC, Wang LW, Wang XR. Interaction models of CYP1A1, GSTM1 polymorphisms and tobacco smoking in intestinal gastric cancer. World J Gastroenterol. 2005;11(38):6056–60.CrossRefPubMedPubMedCentral
24.
Li H, Chen XL, Li HQ. Polymorphism of CYPIA1 and GSTM1 genes associated with susceptibility of gastric cancer in Shandong Province of China. World J Gastroenterol. 2005;11(37):5757–62.CrossRefPubMedPubMedCentral
25.
Nan HM, Song YJ, Yun HY, Park JS, Kim H. Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer. World J Gastroenterol. 2005;11(25):3834–41.CrossRefPubMedPubMedCentral
26.
Roth MJ, Abnet CC, Johnson LL, Mark SD, Dong ZW, Taylor PR, et al. Polymorphic variation of Cyp1A1 is associated with the risk of gastric cardia cancer: a prospective case-cohort study of cytochrome P-450 1A1 and GST enzymes. Cancer Causes Control. 2004;15(10):1077–83.CrossRefPubMed
27.
Suzuki S, Muroishi Y, Nakanishi I, Oda Y. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol. 2004;39(3):220–30.CrossRefPubMed
28.
Zhou T, Fan W, Han W, Gao YJ, Yuan MB, Li JM, et al. Genotypes of cytochrome P450 1A1 and frequent risk factors of gastric cancer in the Han people in China. J Shandong Univ Health Sci. 2007;45(1):71–5. Chinese.
29.
Shen HX, Fu Y, Yuan Y, Di YL, Fu Q, Zhang KL, et al. cytochrome P450 1A1genetic polymorphisms and gastric cancer susceptibility study. J Dalian Med Univ. 2005;27(1):22–4. 67. [Chinese].
30.
Shen J, Wang RT, Xin HX, Wang LW, Wang CX, Wang BY, et al. Research on the interaction models of cytochrome P450 1A1 polymorphism(s) in the agents of stomach cancer. Chin J Prev Med. 2001;35(3):167–70 [Chinese].
31.
Huang X, Tang GD, Jiang HX, Huang JA, Tan ZR, Liang ZH, et al. ssociation between genetic polymorphisms of CYP1A1, GSTM1 and gastric cancer susceptibility in Guangxi Province of China. Chin J Modern Med. 2012;22(8):27–30 [Chinese].
32.
Huang X, Tang GD, Jiang HX, Huang JA, Tan ZR, Liang ZH, et al. Association between genetic polymorphisms of CYP 1A1 and gastric cancer susceptibility in Guangxi province of China. Int J Dig Dis. 2010;30(5):304–6. [Chinese] doctoral dissertation.
33.
Shen J, Wang RT, Xin HX, Wang LW, Wang CX, Wang BY, et al. Case–control study of the polymorphisms of phase I and phase II metabolic genes and stomach cancer susceptibility. Tumor. 2002;22(1):9–13.
34.
Li HQ, Zhou T, Wen PE, Yang RS, Jin SK. A Study of CYP1A1 and GSTM1 genotypes associated with susceptibility to gastric cancer, chronic atrophic gastritis and gastric ulcer diseases. China Cancer. 2002;11(1):25–8.
35.
Han F, Wang X, Wang X, Luo Y, Li W. Meta-analysis of the association of CYP1A1 polymorphisms with gastric cancer susceptibility and interaction with tobacco smoking. Mol Biol Rep. 2012;39(8):8335–44.CrossRefPubMed
36.
Guo R, Guo X. Quantitative assessment of the associations between CYP1A1 polymorphisms and gastric cancer risk. Tumour Biol. 2012;33(4):1125–32.CrossRefPubMed
37.
Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, et al. Systematic review and metaanalysis of the association between{h}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol. 2005;162(3):201–11.CrossRefPubMed
38.
Camargo MC, Mera R, Correa P, Peek Jr RM, Fontham ET, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(9):1674–87.CrossRefPubMed
39.
Xue H, Ni P, Lin B, Xu H, Huang G. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: a HuGE review and meta-analysis. Am J Epidemiol. 2011;173(4):363–75.CrossRefPubMed
40.
Xue H, Lu Y, Lin B, An J, Chen J, Tang F, et al. The Effect of XPD/ERCC2 Polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis. PLoS One. 2012;7(9):e43431.CrossRefPubMedPubMedCentral
41.
Xue H, Wang YC, Lin B, An J, Chen L, Chen J, et al. A meta-analysis of interleukin-10-592 promoter polymorphism associated with gastric cancer risk. PLoS One. 2012;7(7):e39868.CrossRefPubMedPubMedCentral
42.
43.
Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37:120–32.CrossRefPubMed
44.
Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol. 2008;37(1):136–46.CrossRefPubMed
Metadata
Title
The effect of CYP1A1 and CYP1A2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis
Authors
Huiping Xue
Yan Lu
Zeyun Xue
Bing Lin
Jinxian Chen
Feng Tang
Gang Huang
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1620-y

Other articles of this Issue 5/2014

Tumor Biology 5/2014 Go to the issue

Research Article

CEP55 contributes to human gastric carcinoma by regulating cell proliferation

Research Article

Association of single nucleotide polymorphisms of nucleotide excision repair genes with laryngeal cancer risk and interaction with cigarette smoking and alcohol drinking

Research Article

CXCR4 as a novel predictive biomarker for metastasis and poor prognosis in colorectal cancer

Research Article

Possible relations between oxidative damage and apoptosis in benign prostate hyperplasia and prostate cancer patients

Research Article

RETRACTED ARTICLE: Lack of association of XRCC1 rs1799782 genetic polymorphism with risk of pancreatic cancer: a meta-analysis

Research Article

The co-expression of telomerase and ALT pathway in human breast cancer tissues
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits